top of page

Journals - All Articles
Search


PHSS News - Autumn update 2025
PHSS News | Open Access | Published 8th October 2025 PHSS News We recently hosted the PHSS Annual Conference, kindly Sponsored by...
lauraclark849
Oct 83 min read
Â


Regulatory Update: September 2025
Review of Developments in GMP and the Regulation of Medicines Sept 2025 EJPPS vol 30.2CÂ INTRODUCTION This month reported issues have...
lauraclark849
Oct 811 min read
Â


Regulatory Update: July 2025
Review of Developments in GMP and the Regulation of Medicines July 2025Â EJPPS vol 30.3A INTRODUCTION During the last 4 weeks there have...
lauraclark849
Oct 813 min read
Â


Regulatory Update: August 2025
Review of Developments in GMP and the Regulation of Medicines August 2025Â EJPPS vol 30.3BÂ This month reported issues have come from the...
lauraclark849
Oct 818 min read
Â


A Comprehensive Review on the Stability and Degradation of Polysorbates in Biopharmaceuticals
Polysorbates (PS), particularly polysorbate 20 (PS20) and polysorbate 80 (PS80), are widely utilized as non-ionic surfactants in biopharmaceutical formulations. Their primary role is to stabilize therapeutic proteins against interfacial stresses encountered during manufacturing, handling, and storage. Despite their widespread use, PS are complex and heterogeneous mixtures prone to degradation. The two primary degradation pathways are hydrolysis and oxidation. Hydrolytic degra
lauraclark849
Oct 844 min read
Â


Biological indicators (BIs) strategy to use in VHP/vHâ‚‚Oâ‚‚ Bio-decontamination cycle development, performance qualification and ongoing re-qualification
Biological indicators of Geobacillus stearothermophilus spores, inoculated on stainless steel carriers within Tyvek® primary packaging are used as a challenge of efficacy for a bio-decontamination cycle during cycle development, performance qualification and subsequent re-qualification, typically to verify a VHP/vH₂O₂ bio-decontamination cycle meets 6log sporicidal requirements.
lauraclark849
Oct 818 min read
Â


Current Developments In Microfluidic Platforms For Controlled Drug Delivery
Technical Review Article | Open Access | Published 8th October 2025 Current Developments In Microfluidic Platforms For Controlled Drug...
lauraclark849
Oct 819 min read
Â


The Role of Depot Injections in Modern Pharmaceutical Sciences: An Evidence-Based Review
Depot injections represent a pivotal advancement in sustained and controlled drug delivery systems, offering prolonged therapeutic effects, enhanced patient compliance, and reduced dosing frequency. This review comprehensively examines the formulation strategies, mechanisms of drug release, clinical applications, and recent innovations in depot injection technologies. Polymeric matrices, lipid-based systems, and in situ forming depots are discussed alongside their pharmacokin
lauraclark849
Oct 814 min read
Â


Brain Targeted Nanocarriers: A Revolutionary Approach for Treating Neurodegenerative Disorders
Neurodegenerative disorders, which include Alzheimer's, Parkinson's, and Huntington's, pose a significant worldwide health concern due to their gradual loss of neurons and cognitive impairment. The impermeability of the blood-brain barrier (BBB), the quick metabolism of medications, and non-specific delivery make traditional treatment approaches ineffective. Because they allow for site-specific drug administration, improve BBB penetration, and increase therapeutic efficacy wh
lauraclark849
Oct 820 min read
Â


Prescriptive Maintenance Strategy for Cost Optimization in CG Membrane Systems within Pharmaceutical Isolators
Maintaining sterility in pharmaceutical isolators hinges on the performance of CG (Ciba Geigy) membranes, which regulate unidirectional laminar airflow across Grade A environments. Traditionally, manufacturers have relied on reactive or time-based membrane replacement strategies—often resulting in high costs, long lead times, and extended equipment downtime. This study presents a prescriptive maintenance approach designed to optimize the lifecycle of CG membranes through targ
lauraclark849
Oct 821 min read
Â
bottom of page
